Literature DB >> 8861138

Antiarrhythmic action of pharmacological administration of magnesium in heart failure: a critical review of new data.

C A Sueta1, J H Patterson, K F Adams.   

Abstract

Congestive heart failure is characterized by contractile dysfunction and frequent complex ventricular ectopy. Despite advances in therapy, mortality from heart failure is substantial, estimated at 10-80 percent per year, and sudden death is common. Magnesium is the second most common intracellular cation, strongly influences cardiac cell membrane function, and is an important catalyst of many enzymatic reactions in the myocyte. Epidemiological studies have implicated magnesium deficit in the genesis of sudden death. Patients with congestive heart failure are predisposed to magnesium deficit for many reasons, including neurohormonal activation, poor gastrointestinal absorption, and drug therapy. Hypomagnesaemia is common in these patients and has been linked to an increased frequency of complex ventricular ectopy. Several early, uncontrolled studies have suggested a beneficial effect of magnesium administration on ventricular arrhythmias in patients with congestive heart failure. Two recent randomized, double blind, placebo-controlled trials have shown that both intravenous and oral administration of magnesium chloride results in a significant reduction in the frequency and complexity of ventricular arrhythmias in patients with congestive heart failure. Magnesium administration is well tolerated and serious adverse effects are rare. The potential mechanisms of the antiarrhythmic action of magnesium and limitations of the available data are discussed. The evidence reviewed suggests that serum magnesium concentrations should be monitored and corrected in patients with congestive heart failure. Ventricular arrhythmias may respond to acute intravenous magnesium administration, which should be considered as early therapy. Further study is needed to define magnesium dose and the effect of concomitant potassium administration. A prospective clinical trial is warranted to determine the chronic effects of magnesium administration in patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8861138

Source DB:  PubMed          Journal:  Magnes Res        ISSN: 0953-1424            Impact factor:   1.115


  6 in total

1.  Hypomagnesemia and cardiovascular system.

Authors:  G Efstratiadis; M Sarigianni; I Gougourelas
Journal:  Hippokratia       Date:  2006-10       Impact factor: 0.471

2.  Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Stephen J Greene; Andrew P Ambrosy; Robert J Mentz; Gregg C Fonarow; Faiez Zannad; Aldo P Maggioni; Marvin A Konstam; Haris P Subacius; Savina Nodari; Javed Butler; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2013-10-04       Impact factor: 2.778

3.  Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study.

Authors:  Chris Adamopoulos; Bertram Pitt; Xuemei Sui; Thomas E Love; Faiez Zannad; Ali Ahmed
Journal:  Int J Cardiol       Date:  2008-07-30       Impact factor: 4.164

4.  Chai-Hu-San-Shen Capsule Ameliorates Ventricular Arrhythmia Through Inhibition of the CaMKII/FKBP12.6/RyR2/Ca2+ Signaling Pathway in Rats with Myocardial Ischemia.

Authors:  Longqing Chen; Rongzhen Liu; Weisong Wang; Congcong Tang; Junning Ran; Wei Huang; Shuqi Li; Jianhe Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-03       Impact factor: 2.650

5.  Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis.

Authors:  Katja M Kanninen; Alexandra Grubman; Aphrodite Caragounis; Clare Duncan; Sarah J Parker; Grace E Lidgerwood; Irene Volitakis; George Ganio; Peter J Crouch; Anthony R White
Journal:  Biol Open       Date:  2013-05-20       Impact factor: 2.422

6.  Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration?

Authors:  Dorit Almoznino-Sarafian; Sylvia Berman; Anat Mor; Miriam Shteinshnaider; Oleg Gorelik; Irma Tzur; Irena Alon; David Modai; Natan Cohen
Journal:  Eur J Nutr       Date:  2007-05-03       Impact factor: 4.865

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.